Biotech & Diagnostics

Sample First, Assay Second: Building a Pre-Analytical Evidence Trail for UK Antibody Testing

When an antibody assay misbehaves, attention usually turns to the plate: the capture antibody, the blocking buffer, the conjugate, the wash step. Yet a substantial share of unexplained variability arrives in the laboratory already formed, sealed inside a collection tube. The specimen has a history, and that history is part of the measurement. Treating it as background noise is a quiet route to misattribution, unnecessary reagent changes and investigations that never converge.

This article sets out a practical way to document the pre-analytical phase for UK antibody laboratories, so that specimen-related contributions can be distinguished from genuine analytical interference and matrix effects.

The Assay Begins Before the Bench

A sandwich immunoassay result is a product of antibody binding, but also of everything that happened to the sample before it was pipetted. Collection device, anticoagulant, venepuncture technique, the interval before centrifugation, transport temperature and the number of freeze-thaw cycles all leave a signature. Some of these signatures are subtle; some can mimic the classic hallmarks of antibody interference, including non-linear dilution, discordant results between platforms and erratic recovery.

In UK service laboratories, the pre-analytical phase spans settings that rarely share a single quality system: NHS phlebotomy clinics, community diagnostic centres, GP practices, research units and, increasingly, home sampling with postal return. Accreditation to ISO 15189 through UKAS requires control of examination processes, but the specimen's journey is only partly within the laboratory's direct control. The practical response is not to take ownership of the entire pathway, but to build a defensible record of it.

Every Tube Carries Its Own Chemistry

Collection devices are not inert. Serum tubes rely on clot activators and, often, a gel barrier; plasma tubes contain EDTA, citrate or heparin, each with its own consequences. EDTA chelates divalent cations and can affect assay formats that depend on them. Citrate introduces a defined dilution that must be accounted for in result interpretation. Heparin can bind certain proteins and, in some systems, influence binding kinetics. Gel separators may shed material or trap cells at the interface.

These effects are assay-specific, which is precisely why documentation matters more than assumption. A tube type that is neutral for one antibody pair may be problematic for another. The audit should capture manufacturer, additive, nominal draw volume and lot number, because a change of tube supplier is a reagent change in all but name.

Haemolysis, Lipaemia and Icterus: Reading the Specimen

Most UK analysers report haemolysis, icterus and lipaemia indices, or HIL. These are useful screening flags, not verdicts. Haemolysis releases haemoglobin and intracellular contents that can increase non-specific binding or interfere optically. Lipaemia scatters light and can distort turbidimetric and some fluorescence measurements. Icterus interferes with certain wavelengths and chemistries.

The audit question is not simply whether HIL is raised, but whether the result changes with it. If signal loss tracks the haemolysis index across a batch, the cause is likely specimen-side. If a single sample is anomalous while its HIL is unremarkable, interference remains a reasonable hypothesis. Recording HIL alongside tube type and transport interval turns a vague observation into testable evidence.

Time and Temperature: The Unrecorded Reagents

Stability windows are usually defined under controlled conditions. Real specimens encounter UK transport realities: same-day courier versus next-day postal return, Friday collections that sit over a weekend, bank holidays, summer heatwaves and winter delays. Ambient excursions are not hypothetical; the record summer temperatures of 2022 demonstrated how quickly uncontrolled transport can exceed assumed limits.

Storage adds another layer. Aliquoting at receipt, recording freeze-thaw counts and specifying thaw conditions are basic disciplines, yet they are often missing from the assay file. A sample that has been frozen and thawed three times is not the same sample that was validated against fresh material.

A Practical Pre-Analytical Audit: Six Fields to Capture

A workable audit does not require exhaustive metadata. It requires consistent capture of the fields most likely to explain variance:

• Collection device: manufacturer, additive, nominal volume, lot number.
• Phlebotomy context: tourniquet time, order of draw, needle gauge, difficult or traumatic draw.
• Handling interval: time to centrifugation, centrifuge settings, time to analysis or storage.
• Transport: mode, duration, temperature monitoring where available.
• Receipt condition: HIL indices, volume, tube integrity, visible haemolysis.
• Storage history: aliquot number, freeze-thaw count, thaw method, storage temperature.

Applied to a defined sample set, these fields allow laboratories to stratify results and test whether apparent assay failures cluster around particular devices or pathways. A recurring pattern is more informative than any single anomalous sample.

When a Pre-Analytical Change Mimics Interference

Interference investigations frequently begin with heterophilic antibodies, rheumatoid factor or human anti-mouse antibodies in mind. Those causes are real, but they should be reached by exclusion rather than default. If a discrepancy appears after a tube supplier change, a switch to postal sampling or a new transport route, the pre-analytical explanation deserves first consideration. Blocking reagents will not correct a specimen that was haemolysed at collection or delayed in transit.

A simple differential is to compare paired collections: same donor, different tube type; same tube type, different transport interval; same sample, fresh versus once-frozen. Where the signal moves with the pre-analytical variable, the analytical investigation can be narrowed accordingly.

Bridging Into Validation and Change Control

Pre-analytical findings should feed the validation dossier rather than remain as informal bench knowledge. Under ISO 15189, method validation and verification should address specimen type, stability and handling. UKAS assessments increasingly expect documented evidence that these factors have been considered, not merely asserted.

For in vitro diagnostic developers, the same logic applies under UKCA marking requirements. Claims about specimen type and stability need supporting data. A pre-analytical audit can supply the raw material for those claims and for change control when devices, couriers or storage arrangements are altered.

An Evidence Trail, Not a Blame Trail

The purpose of this discipline is not to assign fault to phlebotomists or couriers. It is to give the laboratory a factual account of what the assay actually measured. Antibody assays are sensitive tools, and sensitivity extends to the specimen itself. Documenting the tube, the journey and the storage history is a modest administrative burden that pays back in sharper troubleshooting, cleaner validation and fewer investigations that end in speculation.

The sample is not a neutral delivery vehicle for the analyte. It is the first reagent in the assay, and it deserves a record.